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Abstract
Purpose: The CXCR4/CXCL12 chemokine axis may play a critical role in guiding CXCR4+
circulating malignant cells to organ specific locations that actively secrete its ligand CXCL12 (SDF-
1) such as bone, brain, liver, and lungs. We sought to characterize the presence of the CXCR4/
CXCL12 axis in five uveal melanoma (UM) cell lines in vitro. The ability of TN14003, a synthetic
peptide inhibitor that targets the CXCR4 receptor complex, to inhibit this axis was also assessed.
Methods: Immunocytochemistry was performed against CXCR4 to confirm expression of this
chemokine receptor in all five UM cell lines. Flow cytometry was preformed to evaluate CXCR4
cell surface expression on all five UM cell lines. A proliferation assay was also used to test effects
TN14003 would have on cellular proliferation. Inhibition of cellular migration by specifically
inhibiting the CXCR4/CXCL12 axis with TN14003 was also investigated. The binding efficacy of
TN14003 to the CXCR4 receptor was assessed through flow cytometric methods.
Results: The CXCR4 receptor was present on all five UM cell lines. All five cell lines expressed
different relative levels of surface CXCR4. TN14003 did not affect the proliferation of the five cell
lines (p > 0.05). All cell lines migrated towards the chemokine CXCL12 at a level greater than the
negative control (p < 0.05). All 5 cell lines pre-incubated with TN14003 prevented cellular
migration towards chemokine CXCL12 (p < 0.01). TN14003 preferentially binds CXCR4 to native
ligand CXCL12.
Conclusion: Interfering with the CXCR4/CXCL12 axis, using TN14003 was shown to effectively
down regulate UM cell migration in vitro. Knowing that UM expresses the CXCR4 receptor, these
CXCR4+ cells may be less likely to colonize distant organs that secrete the CXCL12 ligand, if
treated with an inhibitor that binds CXCR4. Further studies should be pursued in order to test
TN14003 efficacy in vivo.
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Uveal melanoma is the most common primary intra-ocu-
lar malignant tumor in adults. Despite advances in diag-
nosis and local treatment of patients over the last 30 years,
the mortality rate has remained constant, with 30 to 50%
of patients developing metastatic disease [1]. Due to the
lack of lymphatics in the eye, metastasis of uveal
melanoma occurs via hematogenous dissemination, with
most metastases developing in the liver [2].
Metastatic disease is typically characterized by initial cell
transformation within the primary tumor site followed by
angiogenesis, facilitating nutrient delivery to the newly
transformed cells. Later events include cellular prolifera-
tion and detachment from the local extracellular matrix,
followed by cell migration and intravasation into the
newly formed vessels [3]. Interactions between tumor
cells and the local environment containing secreted chem-
okines are thought to be important in a number of tumor-
igenic processes including the initial cell migration and
intravasation. Therefore, in vitro studies investigating
these interactions are important to further our under-
standing of the steps involved in the metastatic cascade.
It is now well described and understood that chemo-
attractive cytokines referred to as chemokines play a
number of functional roles in tumor biology [4-8]. Chem-
okines are known to mediate leukocyte trafficking, hae-
matopoiesis, inflammation, angiogenesis, and
tumorigenesis [5]. Recent evidence has demonstrated that
chemokines play a critical role in cellular transformation,
tumor growth, homing, and metastasis [9].
These low molecular weight signaling molecules regulate
and direct circulating immune system cells to specific
locations in the body. It has also recently been discovered
that cancer cells, themselves exploit and "hijack" the
chemokine system in order to facilitate their movement,
and extravasate out of the primary site into systemic circu-
lation [6].
It is widely believed that the CXCR4/CXCL12 axis may
play a critical role in guiding circulating malignant cells
(CXCR4+ cells) to organ specific locations that actively
secrete CXCL12 (SDF-1) such as bone, brain, liver, and
lungs [10]. Many animal models have also shown very
impressive results, while inhibiting the CXCR4/CXCL12
axis, significantly inhibiting and delaying the metastatic
process [11,12]. It has also been recently established that
high CXCR4 positivity in primary human uveal
melanoma specimens correlates with cell type, which is a
well established prognostic indicatior for the develop-
ment of metastatic uveal melanoma [13]. Our laboratory
has previously shown that uveal melanoma cellular
migration can be induced in vitro when exposing uveal
melanoma cell lines to exogenous sources of CXCL12
[14]. We have also shown that uveal melanoma cell lines
(92.1, SP6.5, MKT-BR, OCM-1, UW-1) do not express any
detectable levels of CXCL12 when analyzed with quanti-
tative real-time PCR [14]. This is important because epige-
netic silencing of CXCL12 in human colorectal carcinoma
cell lines has shown to promote and even enhance tumor
metastasis in vitro and in vivo [15]. These results suggest
that when autocrine signaling in the CXCR4/CXCL12 axis
is disrupted, tumor cells become more "malignant" due to
the fact that they can more readily sense CXCL12 secreted
from distant sites [15].
We have shown that interfering with the CXCR4/CXCL12
axis using TN14003 in vitro will effectively inhibit tumor
cell migration. Further in vivo studies are warranted to test
the efficacy of TN14003 to inhibit UM metastasis.
Materials and methods
Cell culture
Four human UM cell lines (92.1, SP6.5, MKT-BR, OCM-1)
and one transformed melanocyte cell line (UW-1) were
incubated at 37°C in a humidified 5% CO2 enriched
atmosphere. These cells were cultured with RPMI-1640
medium (Invitrogen), supplemented with 5% heat inacti-
vated fetal bovine serum (FBS; Invitrogen), 1% fungizone
(Invitrogen), and 1% penicillin twice weekly, at every
media change, for normal growth by phase contrast
microscopy. The cultures were grown to confluence and
passaged by treatment with 0.05% trypsin in EDTA (Corn-
ing) at 37°C and washed in 7 ml RPMI-1640 media
before being centrifuged at 120 g for 10 minutes to form
a pellet.
The UM cell lines 92.1, SP6.5, MKT-BR, OCM-1, and UW-
1 had been established by Dr. Jager (University Hospital
Leiden, The Netherlands), Dr. Pelletier (Laval University,
Quebec, Canada), Dr. Belkhou (CJF INSERM, France) and
Dr. Albert (University of Wisconsin-Madision, USA),
respectively [16,17].
Synthetic peptide inhibitor
The CXCR4 synthetic peptide inhibitor was synthesized
and purchased from the Emory University Microchemical
Facility, Winship Cancer Center. The peptide itself is
approximately 2.03 kDa in size and its linear amino acid
sequence is as follows: NH2-RR-Nal-CY-Cit-K-dLys-PYR-
Cit-CR-amide.
Immunocytochemistry
Cytopsins of the 5 UM cell lines were made using a
Cytospin3 machine (Shandon). Cells from culture were
diluted to a concentration of 250,000 cells/ml, and a 300
μL solution at that concentration was placed in each spin
to be evenly plated on each slide. All slides were thenPage 2 of 7
(page number not for citation purposes)
Cancer Cell International 2007, 7:17 http://www.cancerci.com/content/7/1/17immunostained with primary anti-human monoclonal
antibody against CXCR4 (R&D Systems, clone #: 12G5)
using the Ventana™ automated immunostaining machine
programmed to use a standard Avidin-Biotin Complex
method.
Proliferation assay
The Sulforhodamine-B based assay kit (TOX-6, Sigma-
Aldrich, St. Louis, Missouri, USA) was performed accord-
ing to the National Cancer Institute protocol [18]. Each of
the 5 UM cell lines (92.1, SP6.5, MKT-BR, OCM-1, UW-1)
was seeded into wells at a concentration of 5.0 × 103 cells
per well, with twelve wells per cell line. A row of twelve
wells containing only RPMI-1640 medium was used as a
control. Cells were allowed to adhere overnight. The
CXCR4 peptide inhibitor TN14003 was added the previ-
ous day to six of the twelve wells per cell line at a concen-
tration of 4 ng/ml [12]. Cells were then allowed to
incubate for 48 hours following the addition of TN14003.
Following this 48 hour period, cells were fixed to the bot-
tom of the wells using a solution of 50% Trichloroacetic
acid (TCA) for 1 hour at 4°C. Plates were then rinsed with
distilled water, to remove the TCA and excess media, then
the plates were air dried. The Sulforhodamine-B dye solu-
tion was then added to each well and allowed to stain for
25 minutes. The Sulforhodamine-B solution was subse-
quently removed by washing with a 1% acetic acid solu-
tion and once more allowed to air dry. The dye that had
become incorporated into the fixed cells at the bottom of
the wells was solubilized in a 10 mM solution of Tris. The
absorbance of the solute was measured using a microplate
reader at a wavelength of 565 nm.
Cell migration assay
The migratory and inhibitory properties of 5 UM cell lines
(92.1, MKT-BR, OCM-1, SP6.5, and UW-1) for the
CXCR4/CXCL12 chemokine axis were investigated using a
QCM™ 24-Well Colorimetric Cell Migration Assay
(Chemicon). This assay is based on the Boyden chamber
system that contains smaller well inserts. These well
inserts have a PET membrane made of a polycarbonate
material perforated with 8 μm pores. 5.0 × 105 cells were
then placed in the upper chamber and re-suspended in
RPMI serum-free media. The lower chamber contained
CXCL12 (SDF-1α) also re-suspended in serum free media
at a pre-determined optimum concentration range 200
ng/ml [12]. Test cells were pre-incubated with TN14003 a
2.04 kDa CXCR4 peptide inhibitor at a pre-determined
concentration range of 4 ng/ml [12], before being placed
in the upper chamber of the migration assay. Appropriate
positive and negative controls (10% FBS [+], Serum Free
Media [-]) were also used. These plates were incubated for
24 h at 37°C in a 5% CO2 supplemented atmosphere. Fol-
lowing incubation, cells that did not migrate were
removed from the top of the insert with sterile cotton
swabs. Cells that migrated were then stained, eluted from
the bottom of the wells, and the optical density of the
stain released from the well was read at an O.D of 565 nm.
Flow cytometry
The CXCR4 cell surface expression was measured and
quantified using a Flurokine: Cytokine Flow Cytometry
Kit for human SDF-1α Biotin Conjugate (R&D Systems).
Cells from culture were scrapped from the bottom of each
flask in order to avoid cell surface receptor damage due to
trypsinization of adherent cells. Once scrapped, cells were
washed twice in 10 mM HBSS (invitrogen), centrifuged at
500 × g for 5 minutes to avoid any cross reactivity with
endogenous cytokine secretions. Preceding the washes,
cells were counted and seeded in 1.5 ml tubes at a final
concentration of 4 × 106 cells/ml. 10 μL of the bioti-
nylated cytokine reagent was added to each vial contain-
ing the cell lines (92.1, SP6.5, MKT-BR, OCM-1, UW-1),
10 μL of biotinylated negative control reagent was added
to separate vials containing each of the 5 cells lines as an
appropriate negative control for this experiment. All vials
were incubated for 60 minutes at 5°C as per protocol
instructions. Then 10 μL of the avidin-FITC reagent was
added to each tube and were incubated for 30 min. at 5°C
in the dark as per protocol instructions. The vials contain-
ing the cell reaction mixture were then washed twice with
2 mL of RDF1 buffer provided with the kit in order to
remove unreacted avidin-fluorescein. The cells were then
finally resuspended in 200 μL of RDF1 buffer for flow
cytometric analysis.
Statistical analysis
Results from the migration assay for each cell line (cells
incubated with TN14003) were directly compared to a
matched group of cells incubated solely with CXCL12
using a Student's t-test. A significant result was considered
when a p-value < 0.05 was obtained. Results from the pro-
liferation assay for each cell line (cells incubated with
TN14003) were directly compared to a matched group of
cells that did not contain any inhibitor using a Student's
t-test. A significant result was considered when a p-value <
0.05 was obtained.
Results
Immunocytochemistry
All 5 UM cell line cytospins (92.1, SP6.5, MKT-BR, OCM-
1, UW-1) stained positive for the CXCR4 receptor. All the
slides displayed cytoplasmic staining of the receptor in the
cell lines when viewed under a light microscope at a mag-
nification of 400x (Figure 1). Cells used in all the immu-
nocytochemistry were fixed with 4% paraformaldehyde,
and therefore, cell membranes of all 5 UM cell lines were
permeabilized. This allowed the CXCR4 anti-body to stain
internalized cytoplasmic CXCR4 receptor complexes. This
occurs due to a response to ligand stimulation, where thePage 3 of 7
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by clathrin-coated vesicles [19].
Proliferation assay
The proliferation rate of the 5 UM cell lines when pre-
incubated with TN14003 did decrease slightly in all 5 cell
lines, but was not statistically significant (p > 0.05) when
compared back to the lines that were not pre-incubated
with the peptide inhibitor (Figure 2).
Migration assay
All cell lines migrated towards the chemokine CXCL12
(200 ng/ml) at a level greater than the negative control (p
< 0.05). All 5 cell lines pre-incubated with TN14003 (4
ng/ml) did not migrate towards the chemokine CXCL12
(p < 0.01 in all cases). A student's t-test was used in order
to ascertain a significant change between groups that con-
tained the inhibitor and the groups that did not contain
the inhibitor. The 10% FBS (positive control) gave the
highest levels of migration for each cell line. The serum-
free medium (negative control) caused little to no migra-
tion in all cases (Figure 3).
Flow cytometry
Cell surface expression of CXCR4 on the 5 uveal
melanoma cell lines was verified using Fluorokine:
Cytokine Flow Cytometry Reagents for Human SDF-1α
Biotin Conjugate (R&D Systems). All 5 cell lines expressed
different relative levels of the cell surface receptor CXCR4
(Table 1).
We also analyzed if TN14003 (4 ng/ml) would bind to
cell surface CXCR4 receptors and shift the binding of the
biotinylated SDF-1α cytokine, in turn causing a shift in
the level of florecesence when being read by the flow
cytometer. A negative shift in overall fluorescence was
observed for all 5 cell lines when pre-incubated with
TN14003 (4 ng/ml) for 5 minutes prior to treatment with
SDF-1α biotinylated cytokine (Table 1).
We have also shown that TN14003, a CXCR4 peptide
receptor antagonist, did indeed bind to the CXCR4 recep-
tor shifting the binding of biotinylated ligand SDF-1α
(CXCL12) in all 5 cell lines used. This proves active bind-
ing of the inhibitor which adversely shifted the mean flu-
orescent values of all 5 UM cell lines pre-incubated with
the drug at a very low concentration (4 ng/ml) (Figure 4).
Discussion
There has recently been an overwhelming amount of evi-
dence suggesting that the CXCR4/CXCL12 chemokine sig-
naling axis may play an integral role in the metastatic
progression of many tumor types. It has been shown that
CXCR4 may have a prognostic value when expressed in
certain tumors such as esophageal cancer [20]. These
authors have demonstrated that positive CXCR4 expres-
sion in the primary tumor post pre-operative chemoradi-
otherapy correlates very strongly with progression to
distant metastasis, which provides clinicians with an inde-
pendent prognostic factor for esophageal squamous cell
carcinomas [20]. In non-small cell lung cancer it has been
shown that the CXCR4 receptor, quantified by real-time
Immunocytochemistry for CXCR4Figure 1
Immunocytochemistry for CXCR4. a) Photomicrograph of the MKT-BR cell line (cytospin) stained for CXCR4 (400X) 
displaying mainly cytoplasmic expression of the receptor. Mild nuclear staining is also evident in this image. b) Photomicrograph 
of the negative control for the MKT-BR cell line (400X).Page 4 of 7
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patients that developed clinical metastasis than in those
that did not develop metastasis [21]. Cutaneous
melanoma immunohistocemical studies have also shown
that CXCR4 is a predictor of poor prognosis [22]. Further
studies have analyzed the expression of CXCR4 in metas-
tasis of human cutaneous melanomas, and have conferred
active CXCR4 expression and displayed the possibility of
interfering with this axis in order to inhibit metastasis
using a novel inhibitor AMD3100 [23]. We have revealed
expression of a functional CXCR4 receptor in all 5 uveal
melanoma cell lines that were studied. We have also pre-
viously shown that CXCL12 is not expressed in any these
five cell lines via real-time PCR anaylsis [14]. This point is
particularly interesting to note due to the fact that it has
previously been shown in colorectal carcinoma that when
endogenous sources of CXCL12 are epigenetically
silenced, these cells more readily metastasize compared to
those that engage in CXCR4/CXCL12 autocrine signaling
[15]. This suggests that human uveal melanoma cell lines
will be more likely to have a greater metastatic potential
than other cell lines that actively produce CXCL12 thus
creating an autocrine signaling loop.
The inhibitory potential of TN14003 a CXCR4 peptide
antagonist has been previously studied in inhibiting
breast cancer metastasis [12] and inhibiting the migratory
and invasive ability of human pancreatic cancer cell lines
[24]. Both studies concluded that TN14003 was a very
effective inhibitor of the CXCR4/CXCL12 chemokine axis,
and may be a possible future therapy for breast and pan-
creatic cancer. We showed that TN14003 at concentra-
tions of 4 ng/ml is extremely effective at inhibiting the
migratory ability of human uveal melanoma cell lines.
TN14003 did not significantly reduce the proliferative
ability of the cells due to the fact that CXCL12 is not pro-
duced by these cell lines. This provides further evidence
that an autocrine loop is not active in these particular cell
lines.
The effect of TN14003 on UM cellular proliferationFigure 2
The effect of TN14003 on UM cellular proliferation. A bar graph depicting unaffected cellular proliferation of five UM 
cell lines when incubated with TN14003 (p > 0.05).Page 5 of 7
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ent relative surface expression of the CXCR4 receptor in
the UM cell lines. Cells lines previously described as hav-
ing a higher invasive and proliferative potential in vitro
correlated with higher CXCR4 expression. For example,
the 92.1 cell line has been previously characterized in
vitro [25] and in vivo [26] as having a very high metastatic
potential relative to other human UM cell lines such as
SP6.5, MKT-BR, OCM-1, and UW-1.
Our study has shown that 92.1 does indeed have higher
expression of surface CXCR4 relative to the other 4 UM
cell lines used this experiment. This may implicate that
CXCR4 may be necessary in higher concentration in order
to achieve a greater metastatic potential. Knowing this,
further in vivo studies should be preformed in order to
substantiate the previously mentioned hypothesis.
Conclusion
The characterization of the CXCR4/CXCL12 chemokine
axis in five UM cell lines have shown significant reduction
of cancer cell migration in vitro. We have also displayed
that the TN14003 inhibitor binds CXCR4 with high affin-
ity shifting the binding of its native ligand CXCL12. Cel-
lular proliferation of the UM cell lines tested were not
significantly inhibited by TN14003. This data indicates
that further in vivo studies should be pursued in order to
test TN14003 ability to inhibit UM metastasis.
Table 1: Relative values of mean fluorescent intensity of SDF-1α binding to surface CXCR4 receptors on 5 UM cell lines as measured 
by a flow cytometer.
Cell Line Negative Control SDF-1α TN14003 Inhibitor + SDF-1α
92.1 5.51 346 309
SP6.5 5.08 174 148
MKT-BR 5.85 263 228
OCM-1 6.57 227 196
UW-1 6.97 239 184
Migratory inhibition of UM cell lines using TN14003Fi ure 3
Migratory inhibition of UM cell lines using TN14003. A bar graph depicting the inhibition of cellular migration for five 
UM cell lines when incubated with TN14003 (p < 0.01).Page 6 of 7
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Flow cytometric analysis of CXCR4 cell surface 
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UW-1 using a FITC-avidin complex for biotinylated SDF-1α. 
b) Blue line displaying a negative shift in mean fluorescence 
caused by pre-incubating UW-1 with TN14003 (4 ng/ml) 
before treatment with FITC-avidin complex.Page 7 of 7
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